Inactive Instrument

Theralase Technologies Inc. Stock Toronto S.E.

Equities

TLT

CA88337V1004

Advanced Medical Equipment & Technology

Sales 2024 * 1.65M 1.21M Sales 2025 * 2.28M 1.67M Capitalization 38.8M 28.33M
Net income 2024 * -4M -2.92M Net income 2025 * -5M -3.65M EV / Sales 2024 * 23.5 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 17 x
P/E ratio 2024 *
-8.25 x
P/E ratio 2025 *
-8.25 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.72%
More Fundamentals * Assessed data
Dynamic Chart
Theralase Technologies Inc. announced that it has received CAD 0.7502 million in funding CI
Theralase Technologies Inc. Receives Canadian Cancer Vaccine Patent CI
Theralase Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Theralase Technologies Donates Cool Laser Therapy Technology to Aid in R&D of Treatment for Parkinson's Disease MT
Theralase Technologies Closes C$1.2-Million Private Placement of Share Units MT
Theralase Technologies Inc. announced that it has received CAD 1.200001 million in funding CI
Theralase Technologies Provides Update on Phase II Bladder Cancer Clinical Study MT
Theralase Technologies Inc. Provides Update on Phase II Bladder Cancer Clinical Study CI
Theralase Technologies Raises C$1.17 Million in a Private Placement of Share Units MT
Theralase Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Theralase Technologies Inc. announced that it has received CAD 1.17 million in funding CI
Theralase Technologies Raising up to C$1.5 Million in a Private Placement of Share Units MT
Theralase Technologies Inc. announced that it expects to receive CAD 1.5 million in funding CI
Theralase® Technologies Inc. Announces That It Has Been Granted Clinical Trial Application Amendment by Health Canada Through Receipt of A No Objection Letter for the Optimization of the Phase Ii Non-Muscle Invasive Bladder Cancer Clinical Study CI
Theralase Technologies Inc. Provides Update on Bladder Cancer Clinical Study CI
More news
Managers TitleAgeSince
Founder - 89-08-21
Director of Finance/CFO - 19-06-26
Chief Tech/Sci/R&D Officer - 17-12-31
Members of the board TitleAgeSince
Founder - 89-08-21
Director of Finance/CFO - 19-06-26
Director/Board Member - 07-12-31
More insiders
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.
More about the company